|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:CYP17A1-INTS8 (FusionGDB2 ID:21000) |
Fusion Gene Summary for CYP17A1-INTS8 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CYP17A1-INTS8 | Fusion gene ID: 21000 | Hgene | Tgene | Gene symbol | CYP17A1 | INTS8 | Gene ID | 1586 | 55656 |
| Gene name | cytochrome P450 family 17 subfamily A member 1 | integrator complex subunit 8 | |
| Synonyms | CPT7|CYP17|P450C17|S17AH | C8orf52|INT8|NEDCHS | |
| Cytomap | 10q24.32 | 8q22.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | steroid 17-alpha-hydroxylase/17,20 lyase17-alpha-hydroxyprogesterone aldolaseCYPXVIIcytochrome P450 17A1cytochrome P450, family 17, subfamily A, polypeptide 1cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasiacytochro | integrator complex subunit 8protein kaonashi-1 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | P05093 | Q75QN2 | |
| Ensembl transtripts involved in fusion gene | ENST00000369887, ENST00000489268, | ENST00000520845, ENST00000447247, ENST00000523731, | |
| Fusion gene scores | * DoF score | 7 X 6 X 3=126 | 5 X 5 X 5=125 |
| # samples | 7 | 5 | |
| ** MAII score | log2(7/126*10)=-0.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/125*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CYP17A1 [Title/Abstract] AND INTS8 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | CYP17A1(104596822)-INTS8(95861690), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CYP17A1 | GO:0008202 | steroid metabolic process | 22266943 |
| Hgene | CYP17A1 | GO:0042446 | hormone biosynthetic process | 22266943 |
| Hgene | CYP17A1 | GO:0042448 | progesterone metabolic process | 22266943 |
| Tgene | INTS8 | GO:0016180 | snRNA processing | 16239144 |
| Fusion gene breakpoints across CYP17A1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across INTS8 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | Non-Cancer | TCGA-P8-A5KD-11A | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + |
Top |
Fusion Gene ORF analysis for CYP17A1-INTS8 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000369887 | ENST00000520845 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + |
| 5UTR-3CDS | ENST00000489268 | ENST00000447247 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + |
| 5UTR-3CDS | ENST00000489268 | ENST00000523731 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + |
| 5UTR-intron | ENST00000489268 | ENST00000520845 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + |
| In-frame | ENST00000369887 | ENST00000447247 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + |
| In-frame | ENST00000369887 | ENST00000523731 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000369887 | CYP17A1 | chr10 | 104596822 | - | ENST00000523731 | INTS8 | chr8 | 95861690 | + | 3709 | 469 | 115 | 2196 | 693 |
| ENST00000369887 | CYP17A1 | chr10 | 104596822 | - | ENST00000447247 | INTS8 | chr8 | 95861690 | + | 2404 | 469 | 115 | 2145 | 676 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000369887 | ENST00000523731 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + | 0.000227231 | 0.9997727 |
| ENST00000369887 | ENST00000447247 | CYP17A1 | chr10 | 104596822 | - | INTS8 | chr8 | 95861690 | + | 0.000459861 | 0.9995402 |
Top |
Fusion Genomic Features for CYP17A1-INTS8 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| CYP17A1 | chr10 | 104596821 | - | INTS8 | chr8 | 95861689 | + | 0.13617831 | 0.8638217 |
| CYP17A1 | chr10 | 104596821 | - | INTS8 | chr8 | 95861689 | + | 0.13617831 | 0.8638217 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for CYP17A1-INTS8 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:104596822/chr8:95861690) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CYP17A1 | INTS8 |
| FUNCTION: A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis (PubMed:9452426, PubMed:27339894, PubMed:22266943, PubMed:25301938). Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen synthesis, involves an acyl-carbon cleavage. The 17-alpha hydroxy intermediates, as part of adrenal glucocorticoids biosynthesis pathway, are precursors of cortisol (PubMed:9452426, PubMed:25301938) (Probable). Hydroxylates steroid hormones, pregnenolone and progesterone to form 17-alpha hydroxy metabolites, followed by the cleavage of the C17-C20 bond to form C19 steroids, dehydroepiandrosterone (DHEA) and androstenedione (PubMed:9452426, PubMed:27339894, PubMed:22266943, PubMed:25301938). Has 16-alpha hydroxylase activity. Catalyzes 16-alpha hydroxylation of 17-alpha hydroxy pregnenolone, followed by the cleavage of the C17-C20 bond to form 16-alpha-hydroxy DHEA. Also 16-alpha hydroxylates androgens, relevant for estriol synthesis (PubMed:27339894, PubMed:25301938). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9452426, PubMed:27339894, PubMed:22266943, PubMed:25301938). {ECO:0000269|PubMed:22266943, ECO:0000269|PubMed:25301938, ECO:0000269|PubMed:27339894, ECO:0000269|PubMed:9452426, ECO:0000305|PubMed:8027220}. | FUNCTION: Component of the Integrator complex, a complex involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in their 3'-box-dependent processing. The Integrator complex is associated with the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) and is recruited to the U1 and U2 snRNAs genes. {ECO:0000269|PubMed:28542170}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000447247 | 9 | 26 | 570_603 | 420 | 979.0 | Repeat | Note=TPR 3 | |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000447247 | 9 | 26 | 833_866 | 420 | 979.0 | Repeat | Note=TPR 4 | |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000523731 | 9 | 27 | 570_603 | 420 | 996.0 | Repeat | Note=TPR 3 | |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000523731 | 9 | 27 | 833_866 | 420 | 996.0 | Repeat | Note=TPR 4 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000447247 | 9 | 26 | 250_288 | 420 | 979.0 | Repeat | Note=TPR 1 | |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000447247 | 9 | 26 | 320_356 | 420 | 979.0 | Repeat | Note=TPR 2 | |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000523731 | 9 | 27 | 250_288 | 420 | 996.0 | Repeat | Note=TPR 1 | |
| Tgene | INTS8 | chr10:104596822 | chr8:95861690 | ENST00000523731 | 9 | 27 | 320_356 | 420 | 996.0 | Repeat | Note=TPR 2 |
Top |
Fusion Gene Sequence for CYP17A1-INTS8 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >21000_21000_1_CYP17A1-INTS8_CYP17A1_chr10_104596822_ENST00000369887_INTS8_chr8_95861690_ENST00000447247_length(transcript)=2404nt_BP=469nt ATATGAGCTCAGGCCTGGCTGGGCTCCAGGAGAATCTTTCCACAAGGCAAGAGATAACACAAAGTCAAGGTGAAGATCAGGGTAGCCCTT TAAAAGGCCTCCTTGTGCCCTAGAGTTGCCACAGCTCTTCTACTCCACTGCTGTCTATCTTGCCTGCCGGCACCCAGCCACCATGTGGGA GCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTGTTTTGGCCCAAGAGAAGGTGCCCTGGTGCCAAGTACCCCAAGAGCCTCCTGTC CCTGCCCCTGGTGGGCAGCCTGCCATTCCTCCCCAGACACGGCCATATGCATAACAACTTCTTCAAGCTGCAGAAAAAATATGGCCCCAT CTATTCGGTTCGTATGGGCACCAAGACTACAGTGATTGTCGGCCACCACCAGCTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAGGACTT CTCTGGGCGGCCTCAAATGGTATGTTCAAGATCAGTAAATTTAGAAAAAGCTTCAGAGTCTTTGAAAGGAAACATGGCTGCTTTTCTAAA GAATGTGTGTCTGGGGTTGGAAGATCTGCAGTATGTTTTCATGATTTCTTCACATGAGCTTTTCATTACATTGTTGAAAGATGAAGAACG AAAGCTACTTGTTGATCAGATGAGGAAGAGATCCCCTAGAGTAAATCTGTGCATTAAACCTGTAACTTCATTTTATGATATCCCAGCTTC AGCAAGTGTCAACATTGGTCAGTTAGAGCATCAACTTATATTGTCAGTGGATCCTTGGAGGATTAGACAAATTTTAATTGAATTACATGG TATGACTTCAGAGCGCCAGTTCTGGACAGTGTCTAATAAGTGGGAAGTACCTTCTGTCTATAGTGGTGTTATCCTGGGAATTAAAGACAA TTTAACAAGAGATTTGGTTTATATTCTTATGGCCAAAGGTTTGCACTGCAGTACTGTTAAGGACTTTTCCCATGCTAAACAGCTCTTTGC TGCTTGTTTGGAGTTGGTAACAGAGTTCTCACCGAAGCTTCGTCAGGTCATGCTGAATGAGATGTTGCTTTTGGATATTCATACACACGA AGCTGGGACAGGGCAGGCAGGAGAGAGACCGCCATCCGACCTTATAAGTAGAGTACGAGGCTATCTGGAAATGAGGCTTCCTGATATTCC TCTTCGTCAAGTTATAGCTGAGGAATGTGTTGCCTTTATGTTAAACTGGAGAGAAAATGAATACCTTACACTCCAAGTTCCTGCATTTTT GCTTCAGAGTAATCCATATGTAAAGCTTGGACAGCTTTTAGCAGCTACATGCAAAGAACTTCCAGGCCCTAAAGAAAGTAGACGGACTGC CAAAGACCTTTGGGAAGTTGTTGTTCAAATCTGTAGTGTGTCCAGTCAGCACAAACGAGGAAATGATGGCAGAGTTAGTTTAATAAAACA GAGGGAATCTACGTTAGGTATCATGTATCGGAGTGAACTGCTTTCTTTTATCAAAAAATTACGAGAACCACTCGTTTTGACTATTATTTT ATCACTCTTTGTGAAACTTCACAATGTTCGGGAGGACATTGTGAATGATATTACAGCTGAACACATTTCTATTTGGCCATCTTCCATTCC CAACCTCCAGTCTGTGGACTTTGAAGCTGTGGCAATCACAGTGAAAGAGCTAGTTCGATATACACTCAGTATAAATCCAAATAACCATTC TTGGTTAATTATCCAGGCAGATATTTACTTTGCAACGAATCAGTATTCAGCAGCTCTTCACTATTACCTCCAGGCAGGAGCTGTGTGTTC TGACTTCTTTAACAAGGCTGTGCCCCCTGATGTTTATACAGACCAGGTGGCCATTTTATGTCAGTTCCTCAGAGAAATTGACTACAAAAC AGCGTTTAAATCTCTGCAAGAACAAAACAGTCATGATGCTATGGACTCCTACTACGACTACATATGGGATGTTACCATTTTGGAATACTT GACTTATCTTCATCATAAAAGAGGAGAAACAGATAAAAGACAAATTGCAATCAAAGCCATCGGCCAGACAGAGTTGAATGCAAGCAATCC AGAAGAAGTGTTACAGCTGGCAGCGCAGAGAAGGAAAAAAAAGTTTCTCCAAGCAATGGCAAAACTTTACTTTTAAGCAGTTAAATTTTT TTAACTTTTATTTTTTAAACAATGGGCTAAAAATAAACAGTATTAAAAGGTTAAGTTTATATAATACATATGTACACAATTAGTGGTGTT TTCTTTTCAGACAAAATACTGAAACAAATATTAGTTTAAAAACAAACTATACAGAAGACTTCATACCGTAACAATAAATGTATAGTTTCT >21000_21000_1_CYP17A1-INTS8_CYP17A1_chr10_104596822_ENST00000369887_INTS8_chr8_95861690_ENST00000447247_length(amino acids)=676AA_BP=118 MPQLFYSTAVYLACRHPATMWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTK TTVIVGHHQLAKEVLIKKGKDFSGRPQMVCSRSVNLEKASESLKGNMAAFLKNVCLGLEDLQYVFMISSHELFITLLKDEERKLLVDQMR KRSPRVNLCIKPVTSFYDIPASASVNIGQLEHQLILSVDPWRIRQILIELHGMTSERQFWTVSNKWEVPSVYSGVILGIKDNLTRDLVYI LMAKGLHCSTVKDFSHAKQLFAACLELVTEFSPKLRQVMLNEMLLLDIHTHEAGTGQAGERPPSDLISRVRGYLEMRLPDIPLRQVIAEE CVAFMLNWRENEYLTLQVPAFLLQSNPYVKLGQLLAATCKELPGPKESRRTAKDLWEVVVQICSVSSQHKRGNDGRVSLIKQRESTLGIM YRSELLSFIKKLREPLVLTIILSLFVKLHNVREDIVNDITAEHISIWPSSIPNLQSVDFEAVAITVKELVRYTLSINPNNHSWLIIQADI YFATNQYSAALHYYLQAGAVCSDFFNKAVPPDVYTDQVAILCQFLREIDYKTAFKSLQEQNSHDAMDSYYDYIWDVTILEYLTYLHHKRG -------------------------------------------------------------- >21000_21000_2_CYP17A1-INTS8_CYP17A1_chr10_104596822_ENST00000369887_INTS8_chr8_95861690_ENST00000523731_length(transcript)=3709nt_BP=469nt ATATGAGCTCAGGCCTGGCTGGGCTCCAGGAGAATCTTTCCACAAGGCAAGAGATAACACAAAGTCAAGGTGAAGATCAGGGTAGCCCTT TAAAAGGCCTCCTTGTGCCCTAGAGTTGCCACAGCTCTTCTACTCCACTGCTGTCTATCTTGCCTGCCGGCACCCAGCCACCATGTGGGA GCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTGTTTTGGCCCAAGAGAAGGTGCCCTGGTGCCAAGTACCCCAAGAGCCTCCTGTC CCTGCCCCTGGTGGGCAGCCTGCCATTCCTCCCCAGACACGGCCATATGCATAACAACTTCTTCAAGCTGCAGAAAAAATATGGCCCCAT CTATTCGGTTCGTATGGGCACCAAGACTACAGTGATTGTCGGCCACCACCAGCTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAGGACTT CTCTGGGCGGCCTCAAATGGTATGTTCAAGATCAGTAAATTTAGAAAAAGCTTCAGAGTCTTTGAAAGGAAACATGGCTGCTTTTCTAAA GAATGTGTGTCTGGGGTTGGAAGATCTGCAGTATGTTTTCATGATTTCTTCACATGAGCTTTTCATTACATTGTTGAAAGATGAAGAACG AAAGCTACTTGTTGATCAGATGAGGAAGAGATCCCCTAGAGTAAATCTGTGCATTAAACCTGTAACTTCATTTTATGATATCCCAGCTTC AGCAAGTGTCAACATTGGTCAGTTAGAGCATCAACTTATATTGTCAGTGGATCCTTGGAGGATTAGACAAATTTTAATTGAATTACATGG TATGACTTCAGAGCGCCAGTTCTGGACAGTGTCTAATAAGTGGGAAGTACCTTCTGTCTATAGTGGTGTTATCCTGGGAATTAAAGACAA TTTAACAAGAGATTTGGTTTATATTCTTATGGCCAAAGGTTTGCACTGCAGTACTGTTAAGGACTTTTCCCATGCTAAACAGCTCTTTGC TGCTTGTTTGGAGTTGGTAACAGAGTTCTCACCGAAGCTTCGTCAGGTCATGCTGAATGAGATGTTGCTTTTGGATATTCATACACACGA AGCTGGGACAGGGCAGGCAGGAGAGAGACCGCCATCCGACCTTATAAGTAGAGTACGAGGCTATCTGGAAATGAGGCTTCCTGATATTCC TCTTCGTCAAGTTATAGCTGAGGAATGTGTTGCCTTTATGTTAAACTGGAGAGAAAATGAATACCTTACACTCCAAGTTCCTGCATTTTT GCTTCAGAGTAATCCATATGTAAAGCTTGGACAGCTTTTAGCAGCTACATGCAAAGAACTTCCAGGCCCTAAAGAAAGTAGACGGACTGC CAAAGACCTTTGGGAAGTTGTTGTTCAAATCTGTAGTGTGTCCAGTCAGCACAAACGAGGAAATGATGGCAGAGTTAGTTTAATAAAACA GAGGGAATCTACGTTAGGTATCATGTATCGGAGTGAACTGCTTTCTTTTATCAAAAAATTACGAGAACCACTCGTTTTGACTATTATTTT ATCACTCTTTGTGAAACTTCACAATGTTCGGGAGGACATTGTGAATGATATTACAGCTGAACACATTTCTATTTGGCCATCTTCCATTCC CAACCTCCAGTCTGTGGACTTTGAAGCTGTGGCAATCACAGTGAAAGAGCTAGTTCGATATACACTCAGTATAAATCCAAATAACCATTC TTGGTTAATTATCCAGGCAGATATTTACTTTGCAACGAATCAGTATTCAGCAGCTCTTCACTATTACCTCCAGGCAGGAGCTGTGTGTTC TGACTTCTTTAACAAGGCTGTGCCCCCTGATGTTTATACAGACCAGGTAATAAAACGAATGATAAAATGTTGTTCTTTGCTGAATTGCCA CACACAGGTGGCCATTTTATGTCAGTTCCTCAGAGAAATTGACTACAAAACAGCGTTTAAATCTCTGCAAGAACAAAACAGTCATGATGC TATGGACTCCTACTACGACTACATATGGGATGTTACCATTTTGGAATACTTGACTTATCTTCATCATAAAAGAGGAGAAACAGATAAAAG ACAAATTGCAATCAAAGCCATCGGCCAGACAGAGTTGAATGCAAGCAATCCAGAAGAAGTGTTACAGCTGGCAGCGCAGAGAAGGAAAAA AAAGTTTCTCCAAGCAATGGCAAAACTTTACTTTTAAGCAGTTAAATTTTTTTAACTTTTATTTTTTAAACAATGGGCTAAAAATAAACA GTATTAAAAGGTTAAGTTTATATAATACATATGTACACAATTAGTGGTGTTTTCTTTTCAGACAAAATACTGAAACAAATATTAGTTTAA AAACAAACTATACAGAAGACTTCATACCGTAACAATAAATGTATAGTTTCTTCAAAGGGAGAAGAGATTCACATATCTGATAACAAAATA AACTAGCAATCTAGTTTTCTAATCTACTTTATGAGGCTGGATTTTTTTTTTAGAAAAGCTAATTTAAAATATTTAGAAATAGCTAGCCTA TGTACAGCAAGTTTTCATGTCTTTTTTTAATAAATAGATTTCTAGGAGTCAGTATATATTTAATACTCTTCTTCCTTAAGAAAATAGAAG TTTAGGTCAAGTGTTAAGCTTTATCACTTTGACACTGTCCTTATCTCACAATGGAGGAATTTAGAAAGGACCTTAACAGTTTCACAAACA TAAATAAAGCCTTAGTCACACTAAATTAAAAAAAAAAATTCCTTAGGGATATCTTAGAGTAGTAAAGTGACTTCCTCATATAAATAGTTT GAAAGGGTACTTAAGTTTTTCACCCAAATTGTGATATACAAAAAGGTTATTACCAAGCAACCTACATGTCAAGAAAGCCCCAGTTAGGAA GGAGCCACAGCATTTATCTTGTTTATAATTTCTTTGGTACTCCCACTGTTTAGAGCACAGGTTGAACACCATGTTCATCTAAGCCTTATT AGTTAAAAAATGTGTTATGGCAAGGCAAATAAACTAGTTTAAAAAACATTAAATTTCACCATTTGTAGAAATTCAAGTTTTATAATAGCT TGCTATAGCAGCTATAGATAAATTAGTCACCTTATTACAAAACTAAACCTTTGTAAACAAGTTTAAATTTAATTTTCAAGAACCAAATTG CACTAGTCAAGAGTGTAGGAATTTTGAGAATCTAACAACTAGATTCAAAGTACTGTATCACTTAGTATACCCTTTAAGGTAGCACTTATC CAGTCCAAAACTCCAGTGACAAAATTCCTAGTTTATCAAGATAAACACAGTAACACTGGATTAAAGGAAAAACATTGCTATGGTATAGAC TGTGGTTGGCTTCTATCCAGTAACCTTGGGAATGAAGACATCTTTGTAAACAAGTCCTGCTGTTTCTTTAACAGCTAACATAGGAAATAA TTAAATGTATTCTTTAGTGCCAATTGTAAGTTTTAAAATCAGAATGGCAGTGTAACTTGTGAATTGGCTAGGGCAATCAATCACAGCACT ACTTTCTGTAAAACTTTAGTAGTTCAGTGATACCAGTTCTACCCAATCTTGGTGAATTCCAACTTGTTTGCTTAGTTATCTTCTTTAGTG TTTTCCTGGTGGTTTTTCAGTGCTCTTCGGTGGTGTCATAATGCCTCCATTGCACACTGGTGACAACTGTCCCCCTTTTCTGAAGGTGTT >21000_21000_2_CYP17A1-INTS8_CYP17A1_chr10_104596822_ENST00000369887_INTS8_chr8_95861690_ENST00000523731_length(amino acids)=693AA_BP=118 MPQLFYSTAVYLACRHPATMWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTK TTVIVGHHQLAKEVLIKKGKDFSGRPQMVCSRSVNLEKASESLKGNMAAFLKNVCLGLEDLQYVFMISSHELFITLLKDEERKLLVDQMR KRSPRVNLCIKPVTSFYDIPASASVNIGQLEHQLILSVDPWRIRQILIELHGMTSERQFWTVSNKWEVPSVYSGVILGIKDNLTRDLVYI LMAKGLHCSTVKDFSHAKQLFAACLELVTEFSPKLRQVMLNEMLLLDIHTHEAGTGQAGERPPSDLISRVRGYLEMRLPDIPLRQVIAEE CVAFMLNWRENEYLTLQVPAFLLQSNPYVKLGQLLAATCKELPGPKESRRTAKDLWEVVVQICSVSSQHKRGNDGRVSLIKQRESTLGIM YRSELLSFIKKLREPLVLTIILSLFVKLHNVREDIVNDITAEHISIWPSSIPNLQSVDFEAVAITVKELVRYTLSINPNNHSWLIIQADI YFATNQYSAALHYYLQAGAVCSDFFNKAVPPDVYTDQVIKRMIKCCSLLNCHTQVAILCQFLREIDYKTAFKSLQEQNSHDAMDSYYDYI -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CYP17A1-INTS8 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CYP17A1-INTS8 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CYP17A1-INTS8 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies